Ignite Creation Date:
2026-03-26 @ 3:19 PM
Ignite Modification Date:
2026-03-31 @ 3:50 AM
Study NCT ID:
NCT07321860
Status:
NOT_YET_RECRUITING
Last Update Posted:
2026-01-07
First Post:
2026-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling
Sponsor:
Gipfel Life Sciences GmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-06-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-06-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-01-01
Completion Date Type:
ESTIMATED
First Submit Date:
2026-01-02
First Submit QC Date:
None
Study First Post Date:
2026-01-07
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2026-01-05
Last Update Post Date:
2026-01-07
Last Update Post Date Type:
ACTUAL